[Shanghai RAAS responded to the acquisition of a CDMO factory: intending to supplement the industrialization capabilities of innovative drugs] September 29th. Recently, the news that Shanghai RAAS planned to acquire Boehringer Ingelheim Biopharmaceuticals (China) Co., Ltd. (hereinafter referred to as "Boehringer Biopharmaceuticals") held by Boehringer Ingelheim (China) Investment Co., Ltd. triggered heated discussions in the pharmaceutical circle. On the afternoon of September 28, Xu Jun, vice chairman and general manager of Shanghai RAAS, responded to reporters about the reasons for acquiring the factory, saying that it was a "strategic position and was intended to complement the industrialization capabilities of innovative drugs." Xu Jun also said that the company's layout of innovative drug business is not a "desperate effort". The investment in R&D of innovative drugs is supported by the stable cash flow generated by the blood products business, and adopts a rolling investment and action-based strategy. The company will not invest all the profits from the blood products segment into innovative drugs at once. (China Business News)